{"product_id":"reta","title":"Reta","description":"\u003cdiv class=\"strapi-description text-sm text-[#4B5563] md:text-base line-clamp-6\"\u003e\n\u003cp\u003eRetatrutide research compound. Supplied as a lyophilized peptide for laboratory research applications.\u003c\/p\u003e\n\u003cp\u003ePurity-tested per lot.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFor laboratory research use only. Not for human or veterinary use.\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/div\u003e\u003cdiv class=\"container px-3\"\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Characteristics\" id=\"characteristics\"\u003eCharacteristics\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eMolecular Formula\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eC221H342N46O68\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eCAS\tNumber\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003e2381089-83-2 \u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eMolar Mass\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003e4191.7 g\/mol\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eAmino Acid Sequence\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eHis-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg \u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eSynonyms\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eReta acetate, LY3437943, GLP-1 receptor agonist\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eSolubility\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eWater-soluble\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eOrganoleptic Profile\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eWhite to off-white powder\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eComposition\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eLyophilized powder - requires reconstitution\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"How does Reta work?\" id=\"how-does-reta-work\"\u003eHow does Reta work?\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003cp\u003eReta is a GLP-1 receptor agonist that mimics the effects of native GLP-1, a hormone secreted by the intestinal L-cells in response to nutrient ingestion. By binding to and activating the GLP-1 receptor, Reta stimulates insulin secretion from pancreatic beta-cells in a glucose-dependent manner, while simultaneously inhibiting glucagon secretion from pancreatic alpha-cells. This dual action helps to regulate blood glucose levels and improve glucose homeostasis. In addition to its effects on glucose metabolism, Reta also promotes satiety and reduces food intake by acting on GLP-1 receptors in the hypothalamus, a key region of the brain involved in appetite regulation. By increasing feelings of fullness and reducing hunger, Reta can lead to significant weight loss when combined with a calorie-controlled diet and exercise.\u003c\/p\u003e\n\u003cp\u003eFurthermore, Reta has been shown to exert anti-inflammatory effects by modulating immune cell function and reducing the production of pro-inflammatory cytokines. This anti-inflammatory action may contribute to its beneficial effects on metabolic health, as chronic low-grade inflammation is a hallmark of obesity and related disorders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Benefits\" id=\"benefits\"\u003eBenefits\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\u003cul\u003e\n\u003cli\u003e\u003cp\u003eSignificant weight loss: Reta has demonstrated the ability to promote substantial weight loss in preclinical studies, making it a promising candidate for the treatment of obesity.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eImproved glucose homeostasis: By enhancing insulin secretion and inhibiting glucagon secretion, Reta helps to regulate blood glucose levels and improve glucose tolerance, which is particularly beneficial for individuals with type 2 diabetes.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eReduced inflammation: The anti-inflammatory properties of Reta may help to mitigate the chronic low-grade inflammation associated with obesity, thereby reducing the risk of developing obesity-related comorbidities.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eEnhanced stability and half-life: Reta has been engineered to exhibit improved stability and a prolonged half-life compared to native GLP-1, allowing for less frequent dosing and potentially improving patient compliance.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eTargeted approach to metabolic health: By selectively targeting the GLP-1 receptor, Reta offers a targeted approach to managing obesity and related metabolic disorders, minimizing the risk of off-target effects.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Side Effects\" id=\"side-effects\"\u003eSide Effects\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003cp\u003eBased on the available preclinical data, the most common side effects associated with Reta treatment include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cp\u003eGastrointestinal symptoms: Nausea, vomiting, and diarrhea have been reported in some studies, although these side effects are generally mild and transient.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eInjection site reactions: Local reactions at the injection site, such as redness, swelling, and itching, may occur in some individuals.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eHypoglycemia: In rare cases, Reta may cause low blood sugar levels, particularly when used in combination with other glucose-lowering medications.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIt is important to note that the safety profile of Reta in mammals has not been fully established, and further clinical studies are needed to assess its potential side effects and long-term safety in mammals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Summary\" id=\"summary\"\u003eSummary\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\u003cp\u003eReta is a promising novel peptide that targets the GLP-1 receptor for the treatment of obesity and related metabolic disorders. By mimicking the effects of native GLP-1, Reta promotes weight loss, improves glucose homeostasis, and reduces inflammation. Its enhanced stability and prolonged half-life offer the potential for less frequent dosing and improved patient compliance. While preclinical studies have shown encouraging results, further clinical trials are needed to fully evaluate the efficacy and safety of Reta in mammals. As a targeted approach to managing metabolic health, Reta holds promise as a future therapeutic option for individuals struggling with obesity and its associated comorbidities.\u003c\/p\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"References\" id=\"references\"\u003eReferences\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003col\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/\"\u003eJastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Reta Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Reta for Obesity - A Phase 2 Trial. N Engl J Med. 2023.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37385280\/\"\u003eRosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. Reta, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37947489\/\"\u003eDoggrell SA. Reta showing promise in obesity (and type 2 diabetes). Expert Opin Investig Drugs. 2023.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37086147\/\"\u003eDoggrell SA. Is reta (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37405802\/\"\u003eHarris E. Triple-Hormone Combination Reta Induces 24% Body Weight Loss. JAMA. 2023.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37311727\/\"\u003eUrva S, O'Farrell L, Du Y, Loh MT, Hemmingway A, Qu H, Alsina-Fernandez J, Haupt A, Milicevic Z, Coskun T. The novel GIP, GLP-1 and glucagon receptor agonist reta delays gastric emptying. Diabetes Obes Metab. 2023.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37888926\/\"\u003eElfeki MA, Alkhouri N. Triple-Hormone-Receptor Agonist Reta for Obesity. N Engl J Med. 2023.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37888927\/\"\u003eJastreboff AM, Kaplan LM, Hartman ML. Triple-Hormone-Receptor Agonist Reta for Obesity. Reply. N Engl J Med. 2023.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37902090\/\"\u003eRay A. Reta: a triple incretin receptor agonist for obesity management. Expert Opin Investig Drugs. 2023.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37888925\/\"\u003eBisson A, Fauchier G, Fauchier L. Triple-Hormone-Receptor Agonist Reta for Obesity. N Engl J Med. 2023.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37369789\/\"\u003eSidik S. Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective. Nature. 2023.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38323122\/\"\u003eNaeem M, Imran L, Banatwala UESS. Unleashing the power of reta: A possible triumph over obesity and overweight: A correspondence. Health Sci Rep. 2024.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38511400\/\"\u003eHong SH, Choi KM. Gut hormones and appetite regulation. Curr Opin Endocrinol Diabetes Obes. 2024.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c!--$!--\u003e\u003ctemplate data-dgst=\"BAILOUT_TO_CLIENT_SIDE_RENDERING\"\u003e\u003c\/template\u003e\n  \u003cdiv data-scroll-name=\"Certificate of Analysis (COA)\" class=\"\"\u003e\n  \u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\n    \u003ch2 class=\"mb-6 text-2xl font-semibold leading-[2.25rem] tracking-tight md:my-0\" id=\"certificates\"\u003e\n      Certificate of Analysis (COA)\n    \u003c\/h2\u003e\n  \u003c\/div\u003e\n\n  \u003cdiv class=\"flex w-full flex-row flex-wrap gap-x-0 gap-y-4 md:gap-x-8\"\u003e\n  \n    \u003cdiv class=\"w-1\/2 md:w-fit\"\u003e\n      \u003cdiv class=\"relative overflow-hidden rounded-none\"\u003e\n\t\t\u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0971\/5731\/6908\/files\/Reta.avif?v=1779880734\" target=\"_blank\"\u003e\n        \u003cimg alt=\"Certificate\" loading=\"lazy\" width=\"175\" height=\"227\" decoding=\"async\" data-nimg=\"1\" class=\"h-full w-full max-w-[150px] cursor-pointer rounded-none object-cover md:max-w-[175px]\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0971\/5731\/6908\/files\/Reta.avif?v=1779880734\" style=\"color: transparent;\"\u003e\n\t\t\u003c\/a\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/div\u003e\n\u003c\/div\u003e\n  \u003c!--\/$--\u003e\u003cdiv data-scroll-name=\"Resource\" class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" id=\"resources\"\u003eResource\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"w-full\"\u003e\u003cdiv class=\"text-base text-[#4B5563]\"\u003e\u003cspan\u003eAll products on this site are for research and development use only. Products are not for human consumption of any kind. The statements made on this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure, or prevent any disease. Power Peptides is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Power Peptides is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act. All products are sold for research, laboratory, or analytical purposes only, and are not for human consumption. Power Peptides Products are intended strictly for research purposes only. These products are not approved by the U.S. Food and Drug Administration (FDA) for human consumption or medical use. Under no circumstances should these peptides be used for any purpose other than research. By purchasing or using our peptides, you acknowledge and agree that you will use them solely in accordance with applicable laws and regulations and that you accept full responsibility for their use. Statements made on this website have not been evaluated by the USA Food and Drug Administration.\u003c\/span\u003e\u003c\/div\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"My Store","offers":[{"title":"10mg","offer_id":53240040522028,"sku":"PEP-VIL-RETA-10MG782504","price":148.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0971\/5731\/6908\/files\/reta-card-1739182604732.png?v=1779696809","url":"https:\/\/www.powerpieeptidesus.com\/products\/reta","provider":"Power Peptides","version":"1.0","type":"link"}